Trial Profile
A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With Gemcitabine+Cisplatin or Carboplatin for PD-L1-Selected, Chemotherapy Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Cisplatin; Erlotinib; Gemcitabine
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMpower111
- Sponsors Roche
- 07 Nov 2018 Status changed from completed to discontinued.
- 17 Jan 2018 Status changed from active, no longer recruiting to completed.
- 12 Jan 2018 This trial has been completed in Poland.